Tigenix Sa (TGXSF) 0.7500 $TGXSF
TiGenix: TiGenix to participate or present at key conferences in the second half of 2014
GlobeNewswire - Mon Sep 15, 2:03AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.
European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601
GlobeNewswire - Mon Sep 08, 12:04AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation
Thomson Reuters ONE - Tue Sep 02, 10:29AM CDT
Leuven (BELGIUM) - 1 September, 2014 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company's Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.
TiGenix Business and Financial Update for the First Half of 2014
GlobeNewswire - Tue Aug 26, 12:10AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.
European Medicines Agency renews Marketing Authorisation for ChondroCelect
GlobeNewswire - Tue Jul 01, 12:09AM CDT
TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).
TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis
GlobeNewswire - Mon Jun 30, 2:19AM CDT
TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TiGenix Business Update & Financial Highlights for the First Half of 2013
Marketwire - Tue Aug 20, 12:52AM CDT
TiGenix NV (NYSE Euronext: TIG)
TiGenix Business Update & Financial Highlights for Q1 of 2013
Marketwire - Tue May 14, 12:37AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG)
TiGenix Reports Full Year 2012 Financial Results
Marketwire - Tue Mar 12, 2:09AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG)
TiGenix to Obtain National Reimbursement in Spain for Its Innovative Cartilage Therapy ChondroCelect(R)
Marketwire - Tue Mar 12, 1:55AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect(R) will obtain national reimbursement in Spain.
Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team
LifeSci Advisors Initiates Coverage of TiGenix, NV
Marketwire - Thu Jan 03, 10:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of TiGenix, NV (Euronext Brussels: TIG), a leading cell therapy company that markets the only cell therapy approved to date and fully reimbursed in Europe, ChondroCelect for the repair of knee cartilage. The Company is also developing a series of therapeutic candidates based on its platform technology of expanded stem cells extracted from adipose tissue (eASCs). TiGenix's most advanced clinical program is Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease. Cx601 is currently being tested in the ADMIRE-CD Phase III trial, which began enrolling patients in July 2012. Data from the trial are expected in the second half of 2014.
TiGenix: TiGenix to participate or present at key conferences in the second half of 2014
GlobeNewswire - Mon Sep 15, 2:03AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.
European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601
GlobeNewswire - Mon Sep 08, 12:04AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Paediatric Investigation Plan (PIP) for Cx601, a locally injected stem cell product in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.
TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation
Thomson Reuters ONE - Tue Sep 02, 10:29AM CDT
Leuven (BELGIUM) - 1 September, 2014 -TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company's Chief Medical Officer, and Dr Mary Carmen Diez as its Vice President Medical Affairs and New Product Commercialisation.
TiGenix Business and Financial Update for the First Half of 2014
GlobeNewswire - Tue Aug 26, 12:10AM CDT
TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today.
European Medicines Agency renews Marketing Authorisation for ChondroCelect
GlobeNewswire - Tue Jul 01, 12:09AM CDT
TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic Area (EEA).
TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis
GlobeNewswire - Mon Jun 30, 2:19AM CDT
TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TiGenix Business Update & Financial Highlights for the First Half of 2013
Marketwire - Tue Aug 20, 12:52AM CDT
TiGenix NV (NYSE Euronext: TIG)
TiGenix Business Update & Financial Highlights for Q1 of 2013
Marketwire - Tue May 14, 12:37AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG)
TiGenix Reports Full Year 2012 Financial Results
Marketwire - Tue Mar 12, 2:09AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG)
TiGenix to Obtain National Reimbursement in Spain for Its Innovative Cartilage Therapy ChondroCelect(R)
Marketwire - Tue Mar 12, 1:55AM CDT
TiGenix NV (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect(R) will obtain national reimbursement in Spain.
Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team
LifeSci Advisors Initiates Coverage of TiGenix, NV
Marketwire - Thu Jan 03, 10:00AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of TiGenix, NV (Euronext Brussels: TIG), a leading cell therapy company that markets the only cell therapy approved to date and fully reimbursed in Europe, ChondroCelect for the repair of knee cartilage. The Company is also developing a series of therapeutic candidates based on its platform technology of expanded stem cells extracted from adipose tissue (eASCs). TiGenix's most advanced clinical program is Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease. Cx601 is currently being tested in the ADMIRE-CD Phase III trial, which began enrolling patients in July 2012. Data from the trial are expected in the second half of 2014.
